DDAVP Rhinal Tube Side Effects
Generic name: desmopressin
Note: This document contains side effect information about desmopressin. Some of the dosage forms listed on this page may not apply to the brand name DDAVP Rhinal Tube.
Some side effects of DDAVP Rhinal Tube may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to desmopressin: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking desmopressin (the active ingredient contained in DDAVP Rhinal Tube) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking desmopressin and call your doctor at once if you have any of these serious side effects:
nausea, vomiting, weakness, loss of appetite, headache, feeling restless or irritable, confusion, hallucinations, muscle pain or weakness, and/or seizure;
feeling like you might pass out;
swelling, weight gain; or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).
Less serious side effects of desmopressin may include:
nausea, mild stomach pain;
warmth, redness, or tingly feeling in your face.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.
For Healthcare Professionals
Applies to desmopressin: injectable solution, nasal solution, nasal spray, oral tablet
One review of the literature found that the incidence of thrombotic events associated with the use of DDAVP to reduce blood loss and transfusion requirements in surgical patients was not significantly higher than placebo. In any case, the incidence of thrombosis is rare. One review found only 10 reports of thrombosis over a 4-year period, covering 433,000 doses of DDAVP.
Cardiovascular side effects have infrequently included transient and slight elevations or reductions in blood pressure, a compensatory change in heart rate, and facial flushing with injections of desmopressin (DDAVP). Vasodilation and water retention have occurred. There have been rare reports of thrombotic events (acute cerebral thrombosis, acute myocardial infarction) in some patients after DDAVP injection. At least one case of fatal left coronary thrombosis has been associated with the use of DDAVP.
The risk factors for DDAVP-induced hyponatremia include stress, surgery, anesthesia, narcotics (endogenous release of ADH), vomiting (loss of sodium), liver disease (hindered metabolism of DDAVP), overhydration with hyponatremic fluids, and advanced age. In some cases, fluid restriction, avoidance of hyponatremic solutions, and close monitoring of serum electrolytes and urine output for at least 15 to 20 hours after the administration of DDAVP may be beneficial.
Nervous system side effects have included seizures and/or coma as a result of severe water intoxication and hyponatremia. Other nervous system side effects have included headache and dizziness in less than 3% of patients. DDAVP nasal spray has been infrequently associated with somnolence, lethargy, paresthesias, fatigue, confusion, stupor, malaise, diaphoresis, itchy or light-sensitive eyes, insomnia, chills, warm feeling, and agitation.
Hematologic side effects have included platelet aggregation and thrombocytopenia. These have been seen almost uniquely in patients with von Willebrand's disease Type IIB (DDAVP is contraindicated in these patients).
Local side effects of injections of DDAVP have included intravenous site erythema, swelling, and burning.
Respiratory side effects of intranasal DDAVP have included rhinitis, epistaxis, and nostril pain in 2% to 10% of patients. Apnea and cardiac arrest occurred in one patient.
Gastrointestinal side effects have included mild abdominal cramps and nausea in 2% of patients. Dyspepsia and vomiting have rarely been associated with DDAVP nasal spray.
Hypersensitivity reactions have rarely included anaphylaxis.
Psychiatric side effects have included a single case of paranoid psychosis associated with the use of DDAVP nasal spray.
More DDAVP Rhinal Tube resources
- DDAVP Rhinal Tube Advanced Consumer (Micromedex) - Includes Dosage Information
- DDAVP Rhinal Tube nasal Concise Consumer Information (Cerner Multum)
- DDAVP Rhinal Tube Prescribing Information (FDA)
- Desmopressin Prescribing Information (FDA)
- DDAVP Prescribing Information (FDA)
- DDAVP Concise Consumer Information (Cerner Multum)
- DDAVP MedFacts Consumer Leaflet (Wolters Kluwer)
- Desmopressin Acetate Monograph (AHFS DI)
- Minirin spray MedFacts Consumer Leaflet (Wolters Kluwer)
- Stimate Prescribing Information (FDA)
- Stimate spray MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.